Research Analysts’ Weekly Ratings Updates for Perspective Therapeutics (CATX)

Several analysts have recently updated their ratings and price targets for Perspective Therapeutics (NYSEAMERICAN: CATX):

• 3/23/2026 – Perspective Therapeutics had its price target raised by HC Wainwright from $12.00 to $13.00. They now have a “buy” rating on the stock.
• 3/18/2026 – Perspective Therapeutics had its price target raised by B. Riley Financial, Inc. from $11.00 to $13.00. They now have a “buy” rating on the stock.
• 3/18/2026 – Perspective Therapeutics had its price target raised by UBS Group AG from $7.00 to $8.00. They now have a “buy” rating on the stock.
• 3/18/2026 – Perspective Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $11.00 price target on the stock.
• 3/17/2026 – Perspective Therapeutics was given a new $12.00 price target by Truist Financial Corporation.
• 3/17/2026 – Perspective Therapeutics had its price target lowered by Royal Bank Of Canada from $18.00 to $14.00. They now have an “outperform” rating on the stock.
• 3/17/2026 – Perspective Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $14.00 price target on the stock.
• 2/19/2026 – Perspective Therapeutics is now covered by Piper Sandler. They set an “overweight” rating and a $16.00 price target on the stock.
• 2/19/2026 – Perspective Therapeutics is now covered by Piper Sandler. They set an “overweight” rating and a $16.00 price target on the stock.

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.